Cancer-expanded myeloid-derived suppressor cells induce anergy of NK cells through membrane-bound TGF-β1

Journal of Immunology

Volumn 182, Issue 1, 2009, Pages 240-249

  Hequan, Li ^a   Yanmei, Han ^b   Qiuli, Guo ^b   Minggang, Zhang ^b   Xuetao, Cao ^a,b  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; NATURAL KILLER CELL RECEPTOR NKG2D; TRANSFORMING GROWTH FACTOR BETA1; MEMBRANE PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CELL FUNCTION; CLONAL ANERGY; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; IN VITRO STUDY; IN VIVO STUDY; LIVER CANCER; LIVER CELL; MOUSE; NATURAL KILLER T CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; SPLEEN CELL; SUPPRESSOR CELL; ANIMAL; BONE MARROW CELL; C57BL MOUSE; CANCER TRANSPLANTATION; CELL DIFFERENTIATION; COCULTURE; IMMUNOLOGY; LIVER TUMOR; METABOLISM; MOUSE MUTANT; NATURAL KILLER CELL; PATHOLOGY; PHYSIOLOGY; PROTEIN BINDING; TRANSGENIC MOUSE; TRANSPLANTATION; TUMOR CELL LINE; TUMOR ESCAPE;

ANIMALS; CELL DIFFERENTIATION; CELL LINE, TUMOR; CLONAL ANERGY; COCULTURE TECHNIQUES; KILLER CELLS, NATURAL; LIVER NEOPLASMS; LIVER NEOPLASMS, EXPERIMENTAL; MEMBRANE PROTEINS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; MYELOID CELLS; NEOPLASM TRANSPLANTATION; PROTEIN BINDING; TRANSFORMING GROWTH FACTOR BETA1; TUMOR ESCAPE;

EID: 59849126377     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.182.1.240     Document Type: Article

References (32)

1. Cerwenka, A., and L. L. Lanier. 2001. Natural killer cells, viruses and cancer. Nat. Rev. Immunol. 1: 41-49.
2. Heusela, J. W., and Z. K. Ballasb. 2003. Natural killer cells: emerging concepts in immunity to infection and implications for assessment of immunodeficiency. Curr. Opin. Pediat. 15: 586-593.
3. Lalor, P. F., and D. H. Adams. 2002. The liver: a model of organ-specific lymphocyte recruitment. Expert Rev. Mol. Med. 4: 1-16.
4. Serafini, P., C. De Santo, I. Marigo, S. Cingarlini, L. Dolcetti, G. Gallina, P. Zanovello, and V. Bronte. 2004. Derangement of immune responses by myeloid suppressor cells. Cancer Immunol. Immunother. 53: 64-72.
5. Serafini, P., I. Borrello, and V. Bronte. 2006. Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression. Semin. Cancer Biol. 16: 53-65.
6. + T cells. J. Clin. Invest. 116: 2777-2790.
7. Frey, A. B. 2006. Myeloid suppressor cells regulate the adaptive immune response to cancer. J. Clin. Invest. 116: 2587-2590.
8. Terabe, M., S. Matsui, J. M. Park, M. Mamura, N. Noben-Trauth, D. D. Donaldson, W. Chen, S. M. Wahl, S. Ledbetter, B. Pratt, et al. 2003. Transforming growth factor-β production and myeloid cells are an effector mechanism through which CD1d restricted T cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance: abrogation prevents tumor recurrence. J. Exp. Med. 198: 1741-1752.
9. Kusmartsev, S., F. Cheng, B. Yu, Y. Nefedova, E. Sotomayor, R. Lush, and D. Gabrilovich. 2003. All-trans-retinoic acid eliminates immature myeloid cells from tumor-bearing mice and improves the effect of vaccination. Cancer Res. 63: 4441-4449.
10. Yang, X., J. J. Letterio, R. J. Lechleider, L. Chen, R. Hayman, H. Gu, A. B. Roberts, and C. Deng. 1999. Targeted disruption of SMAD3 results in impaired mucosal immunity and diminished T cell responsiveness to TGF-β. EMBO J. 18: 1280-1291.
11. Raskopf, E., C. Dzienisowicz, T. Hilbert, C. Rabe, L. Leifeld, N. Wernert, T. Sauerbruch, J. Prieto, C. Qian, W. H. Caselmann, and V. Schmitz. 2005. Effective angiostatic treatment in a murine metastatic and orthotopic hepatoma model. Hepatology 41: 1233-1240.
12. Koeppen, H., R. Schwall, and A. Ashkenazi. 2004. Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand cooperates with chemotherapy to inhibit orthotopic lung tumor growth and improve survival. Cancer Res. 64: 4900-4905.
13. + myeloid cells lacking T cell protein tyrosine phosphatase inhibit lymphocyte proliferation by an IFN-γ- and nitric oxide-dependent mechanism. J. Immunol. 171: 726-732.
14. Richman, L. K., R. J. Klingenstein, J. A. Richman, W. Strober, and J. A. Berzofsky. 1979. The murine Kupffer cell. I. Characterization of the cell serving accessory function in antigen-specific T cell proliferation. J. Immunol. 123: 2602-2609.
15. Qian, C., X. Jiang, H. An, Y. Yu, Z. Guo, S. Liu, H. Xu, and X. Cao. 2006. TLR agonists promote ERK-mediated preferential IL-10 production of regulatory dendritic cells (diffDCs) leading to NK cell activation. Blood 108: 2307-2315.
16. Godoy-Ramirez, K., K. Franck, and H. Gaines. 2000. A novel method for the simultaneous assessment of natural killer cell conjugate formation and cytotoxicity at the single-cell level by multi-parameter flow cytometry. J. Immunol. Methods 239: 35-44.
17. Onizuka, S., I. Tawara, J. Shimizu, S. Sakaguchi, T. Fujita, and E. Nakayama. 1999. Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor α) monoclonal antibody. Cancer Res. 59: 3128-3133.
18. Lieberman, L. A., and C. A. Hunter. 2002. Regulatory pathways involved in the infection-induced production of IFN-g by NK cells. Microbes Infect. 4: 1531-1538.
19. Bellone, G., M. Aste-Amezaga, G. Trinchieri, and U. Rodeck. 1995. Regulation of NK cell functions by TGF-β1. J. Immunol. 155: 1066-1073.
20. Castriconi, R., C. Cantoni, M. Della Chiesa, M. Vitale, E. Marcenaro, R. Conte, R. Biassoni, C. Bottino, L. Moretta, and A. Moretta. 2003. Transforming growth factor-β1 inhibits expression of NKp30 and NKG2D receptors: consequences for the NK-mediated killing of dendritic cells. Proc. Natl. Acad. Sci. USA 100: 4120-4125.
21. + regulatory T cells inhibit natural killer cell functions in a transforming growth factor-β-dependent manner. J. Exp. Med. 202: 1075-1085.
22. Zitvogel, L., A. Tesniere, and G. Kroemer. 2006. Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat. Rev. Immunol. 6: 715-727.
23. Smyth, M. J., Y. Hayakawa, K. Takeda, and H. Yagita. 2002. New aspects of natural-killer-cell surveillance and therapy of cancer. Nat. Rev. Cancer 2: 850-861.
24. Groh, V., J. Wu, C. Yee, and T. Spies. 2002. Tumor-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 419: 734-738.
25. Mazzoni, A., V. Bronte, A. Visintin, J. H. Spitzer, E. Apolloni, P. Serafini, P. Zanovello, and D. M. Segal. 2002. Myeloid suppressor lines inhibit T cell responses by an NO-dependent mechanism. J. Immunol. 168: 689-695.
26. + cells. J. Immunol. 161: 5313-5320.
27. Liu, C., S. Yu, J. Kappes, J. Wang, W. E. Grizzle, K. R. Zinn, and H. G. Zhang. 2007. Expansion of spleen myeloid suppressor cells represses NK cell cytotoxicity in tumor-bearing host. Blood 109: 4336-4342.
28. Lanier, L. L. 2005. NK cell recognition. Annu. Rev. Immunol. 23: 225-274.
29. Rabinovich, G. A., D. Gabrilovich, and E. M. Sotomayor. 2007. Immunosuppressive strategies that are mediated by tumor cells. Annu. Rev. Immunol. 25: 267-296.
30. Movahedi, K., M. Guilliams, J. Van den Bossche, R. Van den Bergh, C. Gysemans, A. Beschin, P. De Baetselier, and J. A. Van Ginderachter. 2008. Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity. Blood 111: 4233-4244.
31. Schwartz, R. H. 2003. T cells anergy. Annu. Rev. Immunol. 21: 305-334.
32. Cambier, J. C., S. B. Gauld, K. T. Merrell, and B. J. Vilen. 2007. B-cell anergy: from transgenic models to naturally occurring anergic B cells? Nat. Rev. Immunol. 7: 633-643.